These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1697059)

  • 1. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis.
    Van Wye JE; Collins MS; Baylor M; Pennington JE; Hsu YP; Sampanvejsopa V; Moss RB
    Pediatr Pulmonol; 1990; 9(1):7-18. PubMed ID: 1697059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis.
    Winnie GB; Cowan RG; Wade NA
    J Pediatr; 1989 Feb; 114(2):309-14. PubMed ID: 2915293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.
    Eichler I; Joris L; Hsu YP; Van Wye J; Bram R; Moss R
    J Clin Invest; 1989 Dec; 84(6):1794-804. PubMed ID: 2512330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Passive immunotherapy for treatment of endobronchitis in cystic fibrosis].
    Moss RB
    Infusionsther Transfusionsmed; 1993 Apr; 20 Suppl 1():42-6; discussion 47. PubMed ID: 8499750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotype-specific serum IgG antibodies to lipopolysaccharides of Pseudomonas aeruginosa in cystic fibrosis: correlation to disease, subclass distribution, and experimental protective capacity.
    Schaad UB; Lang AB; Wedgwood J; Buehlamnn U; Fuerer E
    Pediatr Res; 1990 May; 27(5):508-13. PubMed ID: 2111907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis.
    Fick RB; Naegel GP; Squier SU; Wood RE; Gee JB; Reynolds HY
    J Clin Invest; 1984 Jul; 74(1):236-48. PubMed ID: 6429195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis.
    Pamukcu A; Bush A; Buchdahl R
    Pediatr Pulmonol; 1995 Jan; 19(1):10-5. PubMed ID: 7675552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis.
    Smith AL; Redding G; Doershuk C; Goldmann D; Gore E; Hilman B; Marks M; Moss R; Ramsey B; Rubio T
    J Pediatr; 1988 Apr; 112(4):547-54. PubMed ID: 3127569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis.
    Conway SP; Pond MN; Watson A; Etherington C; Robey HL; Goldman MH
    Thorax; 1997 Nov; 52(11):987-93. PubMed ID: 9487348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antibiotic therapy and effects of respiratory physiotherapy techniques in cystic fibrosis patients treated for acute lung exacerbations: an experimental study].
    da Silva Santos CI; Gonçalves de Oliveira Ribeiro MA; Moreno Morcillo A; Fernando Ribeiro A; Dirceu Ribeiro J
    Arch Bronconeumol; 2010 Jun; 46(6):310-6. PubMed ID: 20417019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
    Milla CE; Chmiel JF; Accurso FJ; VanDevanter DR; Konstan MW; Yarranton G; Geller DE;
    Pediatr Pulmonol; 2014 Jul; 49(7):650-8. PubMed ID: 24019259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and laboratory correlations in patients with cystic fibrosis and Pseudomonas aeruginosa infection: The experience of a regional centre.
    Smădeanu R; Moşescu S; Zăpucioiu C; Orăşeanu D
    Pneumologia; 2016; 65(4):201-6. PubMed ID: 29542902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa.
    Jain R; Beckett VV; Konstan MW; Accurso FJ; Burns JL; Mayer-Hamblett N; Milla C; VanDevanter DR; Chmiel JF;
    J Cyst Fibros; 2018 Jul; 17(4):484-491. PubMed ID: 29292092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Affinity constants of naturally acquired and vaccine-induced anti-Pseudomonas aeruginosa antibodies in healthy adults and cystic fibrosis patients.
    Bruderer U; Cryz SJ; Schaad UB; Deusinger M; Que JU; Lang AB
    J Infect Dis; 1992 Aug; 166(2):344-9. PubMed ID: 1634805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency.
    Moss RB; Hsu YP; Sullivan MM; Lewiston NJ
    Pediatr Res; 1986 May; 20(5):453-9. PubMed ID: 3714355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
    Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
    BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Pseudomonas aeruginosa IgG subclass titers in patients with cystic fibrosis: correlations with pulmonary function, neutrophil chemotaxis, and phagocytosis.
    Cowan RG; Winnie GB
    J Clin Immunol; 1993 Sep; 13(5):359-70. PubMed ID: 8245182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide.
    Fick RB; Olchowski J; Squier SU; Merrill WW; Reynolds HY
    Am Rev Respir Dis; 1986 Mar; 133(3):418-22. PubMed ID: 3082264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic duration and changes in FEV
    Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
    BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.